OIPE JC167 JAN 27 2005 PATENT & TRADEMARK OFFICE

1Fw

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	*11

Application Number	10/679,620
Filing Date	October 3, 2003
First Named Inventor	Reinl et al.
Art Unit	1642
Examiner Name	HELMS, Larry Ronald
Attorney Docket Number	34150/0008

ENCLOSURES *(Check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment/Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Supplemental Information Disclosure Statement with PTO/SB-08A
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
  - ☐ Landscape Table on CD
- ☐ After Allowance Communication to TC
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC **(Appeal Notice, Brief, Reply Brief)**
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please Identify below):
  Copies of Cited References
  Return Postcard

Remarks

*Total number of pages does not include total number of pages of cited references

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	McDonough Holland & Allen PC		
Signature			
Printed name	Michelle L. Samonek		
Date	January 25, 2005	Reg. No.	54,421

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Connie Evenich	Date	January 25, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.USCourtForms.com

OIPE JC19 JAN 27 2005 PATENT & TRADEMARK OFFICE

IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

APPLICANT(S):	Reinl et al.
APPLICATION NO.:	10/679,620
FILING DATE:	October 3, 2003
TITLE:	Multimeric Protein Engineering
EXAMINER:	HELMS, Larry Ronald
GROUP ART UNIT:	1642
ATTY. DKT. NO.:	34150/0008

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: 1/25/05 By: Connie Evenich
Connie Evenich

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

SIR:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, and without any assertion of prior art effect, the documents listed on the accompanying Form SB/08A are hereby cited and enclosed.

This Supplemental Information Disclosure Statement is being submitted before receipt of a first Office Action on the merits; accordingly, no fee is believed to be due in order to have these documents made of record and considered by the Examiner. However, if it is determined that a fee is required, the Commissioner is hereby authorized to charge to Deposit Account No.

50-2767 any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment to that account.

Should the Examiner have any questions or wish to discuss further this matter, please contact the undersigned at the telephone number provided below.

Respectfully submitted,

Date: January 25, 2005

By: _____
Michelle L. Samonek, Reg. No.:54,421

McDonough Holland & Allen PC
555 Capitol Mall, 9th Floor
Sacramento, CA 95814-4692
Telephone: (916) 444-3900
Facsimile: (916) 325-4587

OIPE JC100
JAN 27 2005
PATENT & TRADEMARK OFFICE

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	8

Complete if Known	
Application Number	10/679,620
Filing Date	10/3/2003
First Named Inventor	Reinl et al.
Art Unit	1642
Examiner Name	HELMS, Larry Ronald
Attorney Docket Number	34150/0008

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number - Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A	US-4,683,195	07/28/1987	MULLIS, et al.	
	B	US-4,683,202	07/28/1987	MULLIS	
	C	US-6,417,429	07/09/2002	HEIN, et al.	
	D	US-2003/0172407	09/11/2003	HEIN, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] - Number[4] - Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 8

	Complete if Known
Application Number	10/679,620
Filing Date	10/3/2003
First Named Inventor	Reinl et al.
Art Unit	1642
Examiner Name	HELMS, Larry Ronald
Attorney Docket Number	34150/0008

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	E	ALT, et al., "Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells", *J Biol. Chem.* (1978) 253:1357-1370	
	F	BARR, "Mammalian subtilisins: the long-sought dibasic processing endoproteases", *Cell* (1991) 66:1-3	
	G	BEAUCAGE, et al., "Deoxynucleoside phosphoramidites—A new class of key intermediates for deoxypolynucleotide synthesis", *Tetrahedron Letts.* (1981) 22:1859-1862	
	H	BENDAHMANE, et al, "The *Rx* Gene from Potato Controls Separate Virus Resistance and Cell Death Responses", *Plant Cell* (1999) 11:781-792	
	I	BENFEY and CHUA, "Regulated Genes in Transgenic Plants", *Science* (1989) 244:174-181	
	J	BENTON, et al., "Screening lambdagt recombinant clones by hybridization to single plaques in situ", *Science* (1977) 196:180-182	
	K	BISARO, et al., "Genetic analysis of tomato golden mosaic virus", *Communications in Molecular Biology: Viral Vectors* (1988) pp. 172-189	
	L	BITTER, et al., "Expression and secretion vectors for yeast", *Methods in Enzymol.* (1987) 153:516-544	
	M	BOSHART, et al., "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus", *Cell* (1985) 41:521-530	
	N	CARTER, et al, "Humanization of an Anti-p185^{HER2} Antibody for Human Cancer Therapy", *Proc. Nat. Acad. Sci. USA,* (1992) 89:4285-4289	
	O	COCKETT, et al., "High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification", *Bio/Technology* (1990) 8(7):662-7	
	P	COLBERRE-GARAPIN, et al., "A new dominant hybrid selective marker for higher eukaryotic cells", *J. Mol. Biol.* (1981) 150(1):1-14	
	Q	CROUSE, et al., "Expression and amplification of engineered mouse dihydrofolate reductase minigenes", *Mol. Cell. Biol.* (1983) 3(2):257-66	
	R	CULLEN, et al., "Functional analysis of the transcription control region located within the avian retroviral long terminal repeat", *Mol. Cell. Biol.* (1985) 5(3):438-447	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	8

	Complete if Known
Application Number	10/679,620
Filing Date	10/3/2003
First Named Inventor	Reinl et al.
Art Unit	1642
Examiner Name	HELMS, Larry Ronald
Attorney Docket Number	34150/0008

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	S	DAWSON, et al., "Modifications of the tobacco mosaic virus coat protein gene affecting replication, movement and symptomatology", *Phytopathology* (1988) 78:783-789	
	T	DAWSON, et al., "cDNA Cloning of the Complete Genome of Tobacco Mosaic Virus and Production of Infectious Transcripts", *Proc. Natl. Acad Sci. USA* (1986) 83:1832-1836	
	U	DAYHOFF, et al., "Establishing homologies in protein sequences", *Methods in Enzymol.* (1983) 91:524-45	
	V	DILLON, "Regulating gene expression in gene therapy", *TIBTECH* (1993) 11:167-172	
	W	DODET, "Commercial prospects for gene therapy – a company survey", *TIBTECH* (1993) 11:182-189	
	X	DONSON, et al., "Systemic Expression of a Bacterial Gene by a Tobacco Mosaic Virus-Based Vector", *Proc. Nat. Acad. Sci. USA* (1991) 88:7204-7208	
	Y	DURING, et al., "Synthesis and self-assembly of a functional monclonal antibody in transgenic Nicotiana tabacum", *Plant Molecular Biology* (1990) 15:281-293	
	Z	DZAU, et al., "Gene therapy for cardiovascular disease", *TIBTECH* (1993) 11:205-210	
	AA	EGEL-MITANI, et al., "A novel aspartyl protease allowing KEX2-independent MF alpha propheromone processing in yeast", *Yeast* (1990) 6(2):127-137	
	BB	EVAN, et al., "Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product", *Mol. Cell. Biol.* (1985) 5:3610-3616	
	CC	FELGNER, et al., "Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure", *Proc. Natl. Acad. Sci. USA* (1987) 84:7413-7417	
	DD	FENDLY, et al., "Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product", *Cancer Res.*, (1990) 50:1550-1558	
	EE	FINDEIS, et al., Targeted delivery of DNA for gene therapy via receptors", *TIBTECH* (1993) 11:202-205	
	FF	FIREK, et al., "Endoplasmic reticulum targeting of active modified beta-glucuronidase (GUS) in transgenic tobacco plants", *Transgenic Res.* (1994) 3(5):326-331	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 8

	Complete if Known
Application Number	10/679,620
Filing Date	10/3/2003
First Named Inventor	Reinl et al.
Art Unit	1642
Examiner Name	HELMS, Larry Ronald
Attorney Docket Number	34150/0008

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	GG	FLYNN, et al., "Peptide-binding specificity of the molecular chaperone BiP", *Nature* (1991) 353(6346):726-30	
	HH	FOECKING, et al., "Powerful and versatile enhancer-promoter unit for mammalian expression vectors", *Gene* (1986) 45(1):101-5	
	II	FRENCH, et al., "Bacterial gene inserted in an engineered RNA virus - efficient expression in monocotyledonous plant-cells", *Science* (1986) 231:1294-1297	
	JJ	FRIEDMAN, "Gene therapy – a new kind of medicine", *TIBTECH* (1993) 11:156159	
	KK	FRIEDMAN and JINNAH, "Gene therapy for disorders of the nervous system", *TIBTECH* (1993) 11:192-197	
	LL	GOSSEN and BUJARD, "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters", *Proc. Natl. Acad. Sci. USA* (1992) 89(12):5547-5551	
	MM	GRUNSTEIN, et al., "Colony hybridization: a method for the isolation of cloned DNAs that contain a specific gene", *Proc. Natl. Acad. Sci. USA.* (1975) 72(10):3961-3965	
	NN	GUBLER, et al., "A simple and very efficient method for generating cDNA libraries", *Gene* (1983) 25(2-3):263-269	
	OO	HAMILTON, et al., "Stable transfer of intact high molecular weight DNA into plant chromosomes", *Proc. Natl. Acad. Sci. USA.* (1996) 93(18) :9975-9	
	PP	HAMLIN and MA, "The mammalian dihydrofolate reductase locus", *Biochem. et Biophys. Acta*, (1990) 1087(2):107-25	
	QQ	HARLOW, et al., *Antibodies: A Laboratory Manual*, (1988) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY:138-243, Table of Contents: iii-ix	
	RR	HOOYKAAS and SCHILPEROORT, "Agrobacterium and plant genetic engineering", *Plant Mol. Biol.* (1992) 19(1):15-38	
	SS	HORSCH, et al., "A simple and general method for transferring genes into plants", *Science* (1985) 227:1229–1231	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 8

	Complete if Known
Application Number	10/679,620
Filing Date	10/3/2003
First Named Inventor	Reinl et al.
Art Unit	1642
Examiner Name	HELMS, Larry Ronald
Attorney Docket Number	34150/0008

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	TT	HUANG, et al., "Glucocorticoid regulation of the Ha-MuSV p21 gene conferred by sequences from mouse mammary tumor virus", *Cell* (1981) 27(2 Pt 1):245-55	
	UU	JANDA, et al., "Induction of an antibody that catalyzes the hydrolysis of an amide bond", *Science,* (1988) 241:1188-1191	
	VV	JANDA, et at., "Catalytic antibodies with lipase activity and R or S substrate specificity", *Science*, (1989) 244:437-440	
	WW	JEFFERSON, et al., "GUS fusions: beta-glucuronidase as a sensitive and versatile gene fusion marker in higher plants", *EMBO J* (1987) 6:3901-3907	
	XX	KNARR, et al., "BiP binding sequences in antibodies", *J Biol Chem.* (1995) 270(46):27589-94	
	YY	KOZAK, "At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells", *J. Mol. Biol.* (1987) 196(4):947-950	
	ZZ	KUMAGAI, et al., "Cytoplasmic inhibition of carotenoid biosynthesis with virus-derived RNA", *Proc. Natl. Acad. Sci. USA* (1995) 92(5):1679-1683	
	AAA	KUMAGAI, et al., "Rapid, high-level expression of biologically active alpha-trichosanthin in transfected plants by an RNA viral vector", *Proc. Nat. Acad. Sci. USA* (1993) 90(2):427-430	
	BBB	KURJAN and HERSHKOWITZ, "Structure of a yeast pheromone gene (MF alpha): a putative alpha-factor precursor contains four tandem copies of mature alpha-factor", *Cell* (1982) 30(3):933-934	
	CCC	LEE, et. al., "BiP and immunoglobulin light chain cooperate to control the folding of heavy chain and ensure the fidelity of immunoglobulin assembly", *Mol Biol Cell.* (1999) 10(7):2209-19	
	DDD	LOGAN and SHENK, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", *Proc. Natl. Acad. Sci. USA* (1984) 81(12):3655-359	
	EEE	LOWY, et al., "Isolation of transforming DNA: cloning the hamster aprt gene", *Cell* (1980) 22(3):817-23	
	FFF	MITANI and CASKEY, "Delivering therapeutic genes – matching approach and application", *TIBTECH* (1993) 11:162-166	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	6	of	8

	Complete if Known
Application Number	10/679,620
Filing Date	10/3/2003
First Named Inventor	Reinl et al.
Art Unit	1642
Examiner Name	HELMS, Larry Ronald
Attorney Docket Number	34150/0008

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	GGG	MORGAN and ANDERSON, "Human gene therapy", *Ann. Rev. Biochem.* (1993) 62:191-217	
	HHH	MULLIGAN, "The basic science of gene therapy", *Science* (1993) 260:926-932	
	III	MULLIGAN and BERG, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase", *Proc. Natl. Acad. Sci. USA* (1981) 78(4):2072-6	
	JJJ	NABEL and FELGNER, "Direct gene transfer for immunotherapy and immunization", *TIBTECH* (1993) 11:211-215	
	KKK	NEEDHAM-VAN DEVANTER, et al., "Characterization of an adduct between CC-1065 and a defined oligodeoxynucleotide duplex", *Nucleic Acids Res.* (1984) 12:6159-6168	
	LLL	ODELL, et al., "Identification of DNA sequences required for activity of the cauliflower mosaic virus 35S promoter", *Nature* (1985) 313(6005):810-2	
	MMM	O'HARE, et al., "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", *Proc. Natl. Acad. Sci. USA* (1981) 78(3):1527-31	
	NNN	O'NEILL, et al., "The alpha-amylase genes in Oryza sativa: characterization of cDNA clones and mRNA expression during seed germination", *Mol. Gen. Genet.* (1990) 221(2):235-244	
	OOO	PAGE and SYDENHAM, "High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells", *Biotechnology* (1991) 9(1):64-68	
	PPP	PASZKOWSKI, et al., "Direct gene transfer to plants", *EMBO J.* (1984) 3:2717-2722	
	QQQ	PEARSON, et al., "High-performance anion-exchange chromatography of oligonucleotides", *J. Chrom.* (1983) 255:137-149	
	RRR	PFEFFER and ROTHMAN, "Biosynthetic protein transport and sorting by the endoplasmic reticulum and Golgi", *Ann. Rev. Biochem.* (1987) 56:829-52	
	SSS	PIETRZAK, et al., "Expression in plants of two bacterial antibiotic resistance genes after protoplast transformation with a new plant expression vector", *Nucleic Acid Res.* (1986) 14(14):5857-5868	
	TTT	POLLACK, et al., "Selective chemical catalysis by an antibody", *Science* (1986) 234(4783):1570-1573	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 8

Complete if Known	
Application Number	10/679,620
Filing Date	10/3/2003
First Named Inventor	Reinl et al.
Art Unit	1642
Examiner Name	HELMS, Larry Ronald
Attorney Docket Number	34150/0008

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	UUU	PORTEOUS and DORIN, "How relevant are mouse models for human diseases to somatic gene therapy?", *TIBTECH* (1993) 11:173-181	
	VVV	ROBINSON, "Gene therapy – proceeding from laboratory to clinic", *TIBTECH* (1993) 11:155	
	WWW	SAMBROOK, J. et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY	
	XXX	SANTERRE, et al., "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", *Gene* (1984) 30:147-156	
	YYY	SCHECHTER and BERGER, "On the size of the active site in proteases. I. Papain", *Biochem. Biophys. Res. Com.* (1967) 27:157-62	
	ZZZ	SCOFIELD, et al., "Molecular Basis of Gene-for-Gene Specificity in Bacterial Speck Disease of Tomato", *Science* (1996) 274(5295):2063-5	
	1	SHIVPRASAD, et al., "Heterologous sequences greatly affect foreign gene expression in tobacco mosaic virus-based vectors", *Virology* (1999) 255(2):312-323	
	2	SIKORA, "Gene therapy for cancer", *TIBTECH* (1993) 11:197-201	
	3	SZYBALSKA and SZYBALSKI, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", *Proc. Natl. Acad. Sci. USA* (1962) 48:2026-2034	
	4	TANG, et al., "Initiation of Plant Disease Resistance by Physical Interaction of AvrPto and Pto Kinase", *Science* (1996) 274(5295):2060-3	
	5	TOLSTOSHEV, "Gene therapy, concepts, current trials and future directions", *Ann. Rev. Pharmacol. Toxicol.* (1993) 33:573-596	
	6	TRAMONTANO, et al., "Catalytic antibodies", *Science* (1986) 234(4783):1566-1570	
	7	TURPEN, et al., "Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus", *BioTechnology* (1995) 13(1):53-57	
	8	VERCH, et al., "Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector", *J. Immunol. Methods* (1998) 220(1-2):69-75	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	8	of	8

Complete if Known	
Application Number	10/679,620
Filing Date	10/3/2003
First Named Inventor	Reinl et al.
Art Unit	1642
Examiner Name	HELMS, Larry Ronald
Attorney Docket Number	34150/0008

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	9	VITALE and DENECKE, "The endoplasmic reticulum-gateway of the secretory pathway", *Plant Cell* (1999) 11(4):615-28	
	10	WALLACE, et al., "A set of synthetic oligodeoxyribonucleotide primers for DNA sequencing in the plasmid vector pBR322", *Gene* (1981) 16(1-3):21-26	
	11	WANG, et al., "Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3' to 5' exonuclease activity", *J. Immunol. Methods* (2000) 233(1-2):167-177	
	12	WIGLER, et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene", *Proc. Natl. Acad. Sci. USA* (1980) 77:3567-70	
	13	WIGLER, et al., "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells", *Cell* (1977) 11:223-32	
	14	WIVEL, "Regulatory considerations for gene-therapy strategies and products", *TIBTECH* (1993) 11:189-191	
	15	WOLF, et al., "Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells", *J. Immunol.* (1991) 146(9):3074-81	
	16	WU and WU, "Delivery systems for gene therapy", *Biotherapy* (1991) 3:87-95	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.